NASDAQ : CNXU
Conexeu Sciences Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 2.83 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 87.25M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 74.00M |
| Enterprise Value | 72.48M |
Dates
| Measure | Value |
|---|
| Earnings Date | Feb 3, 2027 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 30.83M |
| Shares Outstanding | 30.83M |
| Shares Change (YoY) | +112.91% |
| Shares Change (QoQ) | +31.12% |
| Owned by Insiders (%) | 35.78% |
| Owned by Institutions (%) | 8.11% |
| Float | 18.00M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 11.89 |
| P/TBV Ratio | 13.77 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 5.31 |
| Quick Ratio | 1.55 |
| Debt / Equity | 0.08 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -332.94% |
| Return on Assets (ROA) | -170.73% |
| Return on Invested Capital (ROIC) | -190.88% |
| Return on Capital Employed (ROCE) | -224.32% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 4.29 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 32.73 |
| Average Volume (20 Days) | 404,716 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 297,243 |
| Short Previous Month | 210,489 |
| Short % of Shares Out | 0.96% |
| Short % of Float | 1.65% |
| Short Ratio (days to cover) | 1.04 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -13.20M |
| Pretax Income | -13.63M |
| Net Income | -13.63M |
| EBITDA | -13.17M |
| EBIT | -13.20M |
| Earnings Per Share (EPS) | -$0.63 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 1.97M |
| Total Debt | 453,802 |
| Net Cash | 1.52M |
| Net Cash Per Share | $0.05 |
| Equity (Book Value) | 5.85M |
| Book Value Per Share | 0.21 |
| Working Capital | 5.48M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -10.53M |
| Capital Expenditures | -76,229 |
| Depreciation & Amortization | 29,942 |
| Net Borrowing | -92,188 |
| Free Cash Flow | -10.61M |
| FCF Per Share | -$0.34 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -112.91% |
| Shareholder Yield | -112.91% |
| Earnings Yield | -26.36% |
| FCF Yield | -13.54% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |